Please assess the completion status of the following clinical trial:

Trial Title: Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \< 18 years old~* Assessed and/or listed for heart, kidney, liver transplantation~* Planned oral or enteral maintenance immunosuppression with tacrolimus post transplant~* Informed consent of legal guardian~Exclusion Criteria:~* Contra-indications to oral or enteral tacrolimus~* Co-morbidities that preclude standard dosing e.g. significant renal or hepatic insufficiency~* Participation in other investigational drug trials within 30 days of study initiation

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Standard Dosing Arm (Type: ACTIVE_COMPARATOR): Patients in the standard arm will receive standard starting dose of tacrolimus that is clinically used i.e. 0.1 mg/kg/dose twice a day.
- Pharmacogenetic Arm (Type: EXPERIMENTAL): Patients in the pharmacogenetic arm will receive a starting dose that is assigned based on age and CYP3A5 expressor status. Patients that are CYP3A5 expressors will receive the higher end of the dose range compared to non-expressors. All doses recommended represent clinically acceptable and safe dose ranges used at our institution.~CYP3A5 non-expressor starting dose:~Greater than 6 years of age - 0.075 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.1 mg/kg/dose q12 hours~CYP3A5 expressor starting dose:~Greater than 6 years of age - 0.15 mg/kg/dose q12 hours; Less than or equal to 6 years of age - 0.2 mg/kg/dose q12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).